Targets › MC1R
3 programs from 3 companies in 3 trials: 2 Phase 3, 1 Phase 2; Immunology; next expected readout Feb 2027.
G protein-coupled receptor that binds melanocyte-stimulating hormones (alpha, beta, and gamma-MSH) and adrenocorticotropic hormone/ACTH, which are peptide products of the POMC precursor protein. Upon activation, MC1R couples with the G(s) protein, stimulating adenylate cyclase and activating the cAMP-dependent signaling pathway. (UniProt, Q01726)
Open in Phaseline: the race on MC1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tanabe Pharma | Dersimelagon (MT-7117) Melanocortin receptor 1 agonist | MC1R | Phase 3 | EPP | Dec 2027 |
| Clinuvel | Afamelanotide Melanocortin receptor 1 agonist | MC1R | Phase 3 | Vitiligo | – |
| Hudson Biotech | Afamelanotide Melanocortin receptor 1 agonist | MC1R | Phase 2 | NonSegmental Vitiligo | Feb 2027 |
NonSegmental Vitiligo (1) Vitiligo (1) EPP (1)
small molecule (2), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.